Abstract
Clostridium perfringens alpha-toxin is thought to be an important agent in gas gangrene, which is a lifethreatening infection with fever, pain, edema, myonecrosis, and gas production. The toxin (370 residues) is composed of an N-terminal domain (1-250 residues, N-domain) in which the catalytic site is found and a C-terminal domain (251-370 residues, C-domain) responsible for binding to membranes. During the past decade, recombinant DNA technology has been employed to develop second-generation vaccines, including site-directed mutants and the C-domain of the toxin, to prevent gas gangrene. These immunities have led to protection against the lethal effects of wild-type C. perfringens in mice. C-domain vaccines are capable of protecting against heterologous clostridia causing clostridial myonecrosis. This article summarizes the current knowledge on vaccines against alpha-toxin.
Keywords: Alpha-toxin, C-domain, Clostridium perfringens, Gas gangrene, Recombinant vaccine.
Current Pharmaceutical Biotechnology
Title:Vaccines against Clostridium perfringens Alpha-toxin
Volume: 14 Issue: 10
Author(s): Masahiro Nagahama
Affiliation:
Keywords: Alpha-toxin, C-domain, Clostridium perfringens, Gas gangrene, Recombinant vaccine.
Abstract: Clostridium perfringens alpha-toxin is thought to be an important agent in gas gangrene, which is a lifethreatening infection with fever, pain, edema, myonecrosis, and gas production. The toxin (370 residues) is composed of an N-terminal domain (1-250 residues, N-domain) in which the catalytic site is found and a C-terminal domain (251-370 residues, C-domain) responsible for binding to membranes. During the past decade, recombinant DNA technology has been employed to develop second-generation vaccines, including site-directed mutants and the C-domain of the toxin, to prevent gas gangrene. These immunities have led to protection against the lethal effects of wild-type C. perfringens in mice. C-domain vaccines are capable of protecting against heterologous clostridia causing clostridial myonecrosis. This article summarizes the current knowledge on vaccines against alpha-toxin.
Export Options
About this article
Cite this article as:
Nagahama Masahiro, Vaccines against Clostridium perfringens Alpha-toxin, Current Pharmaceutical Biotechnology 2013; 14 (10) . https://dx.doi.org/10.2174/1389201014666131226124348
DOI https://dx.doi.org/10.2174/1389201014666131226124348 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treating Traumatic Stress in Children and Adolescents
Adolescent Psychiatry Chitotriosidase and Alzheimers Disease
Current Alzheimer Research Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Current Alzheimer Research Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Environmentally Friendly Suzuki Aryl-Aryl Cross-Coupling Reaction
Current Organic Chemistry Investigation Binding Patterns of Human Carboxylesterase I (hCES I) with Broad Substrates by MD Simulations
Current Topics in Medicinal Chemistry Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Editorial: Combining Forces to Improve Alzheimer’s Disease Drug Discovery: The Symptomatic Battle
CNS & Neurological Disorders - Drug Targets Biological Importance of Phenol Derivatives as Potent Bioactive Compound: A Review
Letters in Organic Chemistry Current Applications of Models of Genetic Effects with Interactions Across the Genome
Current Genomics The UDP-Glucuronosyltransferases as Oligomeric Enzymes
Current Drug Metabolism Functional Role of Lipoprotein Receptors in Alzheimers Disease
Current Alzheimer Research Interception of Cocaine by Enzyme or Antibody Delivered with Viral Gene Transfer: A Novel Strategy for Preventing Relapse in Recovering Drug Users
CNS & Neurological Disorders - Drug Targets Cyanopeptides: A New and Nearly Inexhaustible Natural Resource for the Design and Structure-Activity Relationship Studies of New Inhibitors of Trypsin-like Serine Proteases
Current Enzyme Inhibition Patient Involvement and Shared Decision-Making in Mental Health Care
Current Clinical Pharmacology Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design